Clinical Trial

A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if Albumin-bound Paclitaxel/Granulocyte drug can treat patients with recurrent/metastatic breast cancer. The main questions it aims to answer are: To verify the safety of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer. To evaluate the efficacy of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer. To detect the pharmacokinetic behavior of Albumin-bound Paclitaxel/Granulocyte drug in patients with recurrent/metastatic breast cancer.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06496724
Lead Sponsor JIANG LONGWEI
Collaborators: China Pharmaceutical University
Conditions Breast Cancer
Enrollment 1 participants
Start Date 2024-06-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-12